Emergency medicine course - CCT-EM (SEMI)/ MRCEM (UK) at Star Hospitals. Click here to know more! | Please note that STAR Hospitals does not accept online payments and will never ask for an OTP over phone. Please make all payments directly at the hospital.

Book Appointment
1800 102 7827

24/7 Emergency
9100911911 | 8536853853

Book an Appointment Request a Callback

Dr. Sainath Bhethanabhotla

Sr. Consultant & Head, Medical Oncology

10 Years of Experience

Qualifications

  • M.B.B.S from Osmania medical College, Hyderabad
  • M.D (Pediatrics) from All India Institute of Medical Sciences, New Delhi
  • DM (Medical Oncology) from All India Institute of Medical Sciences, New Delhi

Experience

  • MNJ Institute of Oncology & Regional Cancer Centre
  • Krishna Institute of Medical Sciences, Hyderabad
  • Care Hospitals, Hyderabad
  • Soumya Hospitals, Hyderabad

Field of Expertise

  • Breast cancer
  • Gynecological cancer
  • Blood cancer- Leukemia, Lymphoma, myeloma
  • Bone marrow transplant and Cellular therapy
  • Pediatric cancers
  • Gastrointestinal cancers- Stomach, colon, liver, pancreatic cancers
  • Genito-urinary cancers- Prostate, kidney, bladder and testicular cancers
  • Lung cancers
  • Precision oncology
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy
  • Bone marrow transplant and cellular therapy
  • Precision medicine based on personalised genomic testing

Research & Publications

  • 19 publications in highly reputed international journals with total 135 citations
  • Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, et al. Post-treatment PET-CT Rather than Interim PET-CT Using Deauville criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: a Prospective Study Comparing PET-CT versus Conventional Imaging. J Nucl Med. 2016 Oct 6; (IMPACT FACTOR – 10.06)
  • Bhethanabhotla S, Bakhshi S. Presence of risk factors does not affect outcome in early-stage pediatric Hodgkin lymphoma treated with ABVD. Ann Hematol. 2016 Nov 18; (IMPACT FACTOR – 3.63)
  • Bhethanabhotla S, Jain S, Kapoor G, Mahajan A, Chopra A, Vishnubhatla S, et al. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients. Leuk Lymphoma. 2016 Dec 6;1–7. (IMPACT FACTOR – 2.99) 
  • Bhethanabhotla S, Bakhshi S. Reply: Neither post-treatment PET-CT nor interim PET-CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma. J Nucl Med. 2016 Dec 8; (IMPACT FACTOR – 10.06)
  • Bhethanabhotla S, Tiwari A, Sharma MC, Vishnubhatla S, Bakhshi S. Prognostic Significance of IL-6 in Hodgkin Lymphoma. Indian J Pediatr. 2019 June 1;86(6):551–4. (IMPACT FACTOR – 1.96) 
  • Mittal A, Bhethanabhotla S, Ganguly S, Vishnubhatla S, Khadgawat R, Patel C, et al. Late effects in pediatric Hodgkin lymphoma survivors after uniform treatment with ABVD with or without radiotherapy. Pediatr Blood Cancer. 2021 Nov;68(11):e29293. (IMPACT FACTOR – 3.16) 
  • Bhethanabhotla S, Pramanik R, Srivastava P, Mehta P, Patel A, Biswas B, et al. Colorectal Cancer Chemotherapy during COVID-19 Pandemic. Indian J Med Paediatr Oncol. 2020 Mar;41(2):156–60.
  • Bhethanabhotla S, Thukral A, Sankar MJ, Agarwal R, Paul VK, Deorari AK. Effect of position of infant during phototherapy in management of hyperbilirubinemia in late preterm and term neonates: a randomized controlled trial. J Perinatol. 2013 Oct;33(10):795–9. (IMPACT FACTOR – 2.52)
  • Patel A, Gupta VG, Biswas B, Das CK, Batra A, Ganguly S, Bhethanbhotla S et al. Revisiting Fulvestrant Dosing in Uncertain Economic Times. JCO Glob Oncol. 2021 Jan;7:1–3. (IMPACT FACTOR – 1.76) 
  • Patel A, Tannock IF, Srivastava P, Biswas B, Gupta VG, Batra A, Bhethanabhotla S et al. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets. JCO Glob Oncol. 2020 Mar;6:382–6. (IMPACT FACTOR – 1.75)
  • Patel A, Gupta VG, Biswas B, Ganguly S, Das CK, Batra A, Bhethanabhotla S et al. Reply to D. O’Reilly et al. JCO Glob Oncol. 2021 Apr;7:648. (IMPACT FACTOR – 1.75)
  • Taywade SK, Kumar R, Bhethanabhotla S, Bal C. Role of (18)F-FDG PET-CT in Monitoring the Cyclophosphamide Induced Pulmonary Toxicity in Patients with Breast Cancer – 2 Case Reports. Nucl Med Mol Imaging. 2016 Sep;50(3):261–5. (IMPACT FACTOR – 1.75) 
  • Gajendra S, Gogia A, Tanwar P, Sahoo MK, Bhethanabhotla S, Durgapal P, et al. Synchronous metastatic pulmonary adenocarcinoma with small cell lymphoma. Leuk Lymphoma. 2014 Jul;55(7):1678–80. (IMPACT FACTOR – 2.99) 
  • Kakkar A, Rajeshwari M, Bhethanabhotla S, Kaur K, Jain D, Gogia A, et al. Primary diffuse large B-cell lymphoma of the prostate: A report of two cases with diagnostic considerations. J Cancer Res Ther. 2015 Dec;11(4):977–9. (IMPACT FACTOR – 1.33) 
  • Pramanik R, Srivastava P, Sharma A, Mehta P, Patel A, Bhethanbhotla S, et al. Management of Head And-Neck Cancer during COVID-19 Crisis: A Medical Oncology Perspective. Indian J Med Paediatr Oncol. 2020 Mar;41(2):153–5. 
  • Biswas B, Ganguly S, Dabkara D, Ghosh J, Srivastava P, Mehta P, Bhethanabhotla S et al. How we treat lung cancer during SARS-Cov-2 (COVID-19) pandemic in India? Indian Journal of Medical and Paediatric Oncology. 2020 Apr 1;41(2):149. 
  • Das CK, Mahindru S, Patel A, Batra A, Biswas B, Mehta P, Bhethanabhotla S et al. How I Treat Epithelial Ovarian Cancer during COVID-19 Pandemic. Indian J Med Paediatr Oncol. 2020 Mar;41(2):138– 40.
  • Batra A, Mehta P, Patel A, Bhethanabhotla S, Biswas B, Pramanik R, Bhethanabhotla S et al. Breast Cancer Treatment during the COVID-19 Pandemic. Indian J Med Paediatr Oncol. 2020 Mar;41(2):135–7. 
  • Kumar L, Boya RR, Pai R, Harish P, Mookerjee A, Sainath B, et al. Autologous stem cell transplantation for multiple myeloma: Long-term results. The National Medical Journal of India. 2016 Jul 1;29(4):192. (IMPACT FACTOR – 0.59)

Certifications & Memberships

Awards and Achievements
  • Won Sorel Catherine prize for Best post graduate in pediatrics.
  • Stood 2nd in NNF gold medal paper for the year 2012.
  • Received Scholarship for Oral presentation in SIOP-2015
  • Awarded “Abstract achievement award” at American Society of Hematology
  • Meeting on Hematological Malignancies in 2017
Financial District | Banjara Hills

Qualifications

  • M.B.B.S from Osmania medical College, Hyderabad
  • M.D (Pediatrics) from All India Institute of Medical Sciences, New Delhi
  • DM (Medical Oncology) from All India Institute of Medical Sciences, New Delhi

Experience

  • MNJ Institute of Oncology & Regional Cancer Centre
  • Krishna Institute of Medical Sciences, Hyderabad
  • Care Hospitals, Hyderabad
  • Soumya Hospitals, Hyderabad

Field of Expertise

  • Breast cancer
  • Gynecological cancer
  • Blood cancer- Leukemia, Lymphoma, myeloma
  • Bone marrow transplant and Cellular therapy
  • Pediatric cancers
  • Gastrointestinal cancers- Stomach, colon, liver, pancreatic cancers
  • Genito-urinary cancers- Prostate, kidney, bladder and testicular cancers
  • Lung cancers
  • Precision oncology
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy
  • Bone marrow transplant and cellular therapy
  • Precision medicine based on personalised genomic testing

Research & Publications

  • 19 publications in highly reputed international journals with total 135 citations
  • Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, et al. Post-treatment PET-CT Rather than Interim PET-CT Using Deauville criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: a Prospective Study Comparing PET-CT versus Conventional Imaging. J Nucl Med. 2016 Oct 6; (IMPACT FACTOR – 10.06)
  • Bhethanabhotla S, Bakhshi S. Presence of risk factors does not affect outcome in early-stage pediatric Hodgkin lymphoma treated with ABVD. Ann Hematol. 2016 Nov 18; (IMPACT FACTOR – 3.63)
  • Bhethanabhotla S, Jain S, Kapoor G, Mahajan A, Chopra A, Vishnubhatla S, et al. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients. Leuk Lymphoma. 2016 Dec 6;1–7. (IMPACT FACTOR – 2.99) 
  • Bhethanabhotla S, Bakhshi S. Reply: Neither post-treatment PET-CT nor interim PET-CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma. J Nucl Med. 2016 Dec 8; (IMPACT FACTOR – 10.06)
  • Bhethanabhotla S, Tiwari A, Sharma MC, Vishnubhatla S, Bakhshi S. Prognostic Significance of IL-6 in Hodgkin Lymphoma. Indian J Pediatr. 2019 June 1;86(6):551–4. (IMPACT FACTOR – 1.96) 
  • Mittal A, Bhethanabhotla S, Ganguly S, Vishnubhatla S, Khadgawat R, Patel C, et al. Late effects in pediatric Hodgkin lymphoma survivors after uniform treatment with ABVD with or without radiotherapy. Pediatr Blood Cancer. 2021 Nov;68(11):e29293. (IMPACT FACTOR – 3.16) 
  • Bhethanabhotla S, Pramanik R, Srivastava P, Mehta P, Patel A, Biswas B, et al. Colorectal Cancer Chemotherapy during COVID-19 Pandemic. Indian J Med Paediatr Oncol. 2020 Mar;41(2):156–60.
  • Bhethanabhotla S, Thukral A, Sankar MJ, Agarwal R, Paul VK, Deorari AK. Effect of position of infant during phototherapy in management of hyperbilirubinemia in late preterm and term neonates: a randomized controlled trial. J Perinatol. 2013 Oct;33(10):795–9. (IMPACT FACTOR – 2.52)
  • Patel A, Gupta VG, Biswas B, Das CK, Batra A, Ganguly S, Bhethanbhotla S et al. Revisiting Fulvestrant Dosing in Uncertain Economic Times. JCO Glob Oncol. 2021 Jan;7:1–3. (IMPACT FACTOR – 1.76) 
  • Patel A, Tannock IF, Srivastava P, Biswas B, Gupta VG, Batra A, Bhethanabhotla S et al. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets. JCO Glob Oncol. 2020 Mar;6:382–6. (IMPACT FACTOR – 1.75)
  • Patel A, Gupta VG, Biswas B, Ganguly S, Das CK, Batra A, Bhethanabhotla S et al. Reply to D. O’Reilly et al. JCO Glob Oncol. 2021 Apr;7:648. (IMPACT FACTOR – 1.75)
  • Taywade SK, Kumar R, Bhethanabhotla S, Bal C. Role of (18)F-FDG PET-CT in Monitoring the Cyclophosphamide Induced Pulmonary Toxicity in Patients with Breast Cancer – 2 Case Reports. Nucl Med Mol Imaging. 2016 Sep;50(3):261–5. (IMPACT FACTOR – 1.75) 
  • Gajendra S, Gogia A, Tanwar P, Sahoo MK, Bhethanabhotla S, Durgapal P, et al. Synchronous metastatic pulmonary adenocarcinoma with small cell lymphoma. Leuk Lymphoma. 2014 Jul;55(7):1678–80. (IMPACT FACTOR – 2.99) 
  • Kakkar A, Rajeshwari M, Bhethanabhotla S, Kaur K, Jain D, Gogia A, et al. Primary diffuse large B-cell lymphoma of the prostate: A report of two cases with diagnostic considerations. J Cancer Res Ther. 2015 Dec;11(4):977–9. (IMPACT FACTOR – 1.33) 
  • Pramanik R, Srivastava P, Sharma A, Mehta P, Patel A, Bhethanbhotla S, et al. Management of Head And-Neck Cancer during COVID-19 Crisis: A Medical Oncology Perspective. Indian J Med Paediatr Oncol. 2020 Mar;41(2):153–5. 
  • Biswas B, Ganguly S, Dabkara D, Ghosh J, Srivastava P, Mehta P, Bhethanabhotla S et al. How we treat lung cancer during SARS-Cov-2 (COVID-19) pandemic in India? Indian Journal of Medical and Paediatric Oncology. 2020 Apr 1;41(2):149. 
  • Das CK, Mahindru S, Patel A, Batra A, Biswas B, Mehta P, Bhethanabhotla S et al. How I Treat Epithelial Ovarian Cancer during COVID-19 Pandemic. Indian J Med Paediatr Oncol. 2020 Mar;41(2):138– 40.
  • Batra A, Mehta P, Patel A, Bhethanabhotla S, Biswas B, Pramanik R, Bhethanabhotla S et al. Breast Cancer Treatment during the COVID-19 Pandemic. Indian J Med Paediatr Oncol. 2020 Mar;41(2):135–7. 
  • Kumar L, Boya RR, Pai R, Harish P, Mookerjee A, Sainath B, et al. Autologous stem cell transplantation for multiple myeloma: Long-term results. The National Medical Journal of India. 2016 Jul 1;29(4):192. (IMPACT FACTOR – 0.59)

Certifications & Memberships

Awards and Achievements
  • Won Sorel Catherine prize for Best post graduate in pediatrics.
  • Stood 2nd in NNF gold medal paper for the year 2012.
  • Received Scholarship for Oral presentation in SIOP-2015
  • Awarded “Abstract achievement award” at American Society of Hematology
  • Meeting on Hematological Malignancies in 2017

Terms & Conditions | Privacy Policy | © 2008-2023 Star Hospitals, All Rights Reserved